La page que vous recherchez est disponible en anglais.sur notre site global

Pour visiter cette page sélectioner continuer.


Manufacturing Footprint

Capsugel Dosage Form Solutions uses an integrated development program to advance compounds from feasibility and design to commercial manufacture of finished dosage forms. This integrated process - combined with our breadth of technologies - provides our customers with a single partner throughout the development process, thereby reducing project time, cost, complexity and risk. Co-located product development sites in the US, UK and France further enable rapid and optimized product design and development.

A global network of eight world class manufacturing facilities, approved by international regulatory agencies, provides clinical and commercial scale manufacturing for global pharmaceutical and health & nutrition clients around the world. Dedicated non-GMP development suites are in place for pre-clinical feasibility assessments. Dedicated high containment suites are also in place to handle highly potent active ingredients to OEB 4-5 and controlled substances from pre-clinical and clinical studies through commercial manufacture. 

Capsugel's flexible manufacturing footprint support product supply throughout the development cycle across our technology platforms, inclusive of:

Primary and secondary packaging is available for clinical trial material and small-scale commercial manufacturing. Global clinical supplies distribution and logistics is also available, inclusive of cold chain capabilities, through our Xcelience Division.

Infrastructure Overview

Worldwide Locations

Ploërmel, France

  • Pharmaceutical market-segment focus
  • Leading global manufacturer of hormone soft-gel production
  • Center of excellence for steroid hormones and pharmaceutical-grade oils
  • FDA and EMA inspected
  • 3 best-in-class manufacturing units
    • 2 production lines for liquid-fill hard capsules (Licaps®)
    • 11 production lines for soft-gel capsules (SGcaps®)
  • Versatile capability
    • Simple to complex formulations
    • High-containment processing capability for OEB-4 and -5 compounds
  • Pilot and commercial manufacturing
    • cGMP and non-GMP
    • Feasibility, stability and clinical batches

Edinburgh, UK (Scotland)

  • Pharmaceutical market-segment focus
  • Global leading site in liquid-fill hard-capsule production for pharmaceutical segment
  • FDA and MHRA accredited
  • Co-located product development with pilot- and commercial-scale manufacturing
    • cGMP and non-GMP
    • Feasibility, stability and clinical batches
  • Versatile capability
    • Simple and complex liquid and semi-solid formulations
    • Controlled substances (UK Home Office Schedule 2,3,4/III)
    • High containment processing capability for OEB-4 and -5 compounds
    • Cytoxics, antibiotics, peptides and antibodies
  • Specialty capsule coating for targeted delivery
  • Primary and secondary packaging

Bend, USA (OR)

  • Pharmaceutical market-segment focus
    • Drug-product intermediates - SDDs, HME extrudates and nanocrystals
    • Multiparticulate range: extruded / spheronized beads, spray-layered multiparticulates, mini-tablets, and lipid multiparticulates (LMP technology)
    • Tablets, including osmotic and bi-/tri-layered matrices
  • Co-located product development with pilot and commercial manufacturing
    • Dedicated cGMP facility for preparation of kilogram through metric ton (Phase 3) clinical supplies for all technologies
    • Commercial-scale production line for SDD drug-product intermediates
  • Versatile capability
    • Solvent processing
    • High-containment processing capability to OEB-4 and -5 compounds
    • Biologics processing suite

Greenwood, USA (SC)

  • Health and nutrition market-segment focus
  • Select pharmaceutical applications
  • Liquid-fill hard capsule (Licaps®) focus with annual capacity of > 800M units
  • Production line for lipid multiparticulate (LMP) technology
  • Co-located product development site
  • cGMP sample manufacture
  • Bottling and blister packaging
  • JIT (just-in-time) warehousing

Quakertown, USA (PA)

  • Particle size reduction for pharmaceutical market
    • High potency APIs
    • Controlled substances
    • APIs & excipients
  • High potency milling / micronization
  • 2 locations in Quakertown
    • Headquarters (40,000 ft.2)- 1 non GMP suite for R&D; 2 pilot scale GMP suites; 6 commercial scale GMP suites; 2 labs
    • 65,000 ft.2 - houses a customer-dedicated suite, 1 commercial-scale GMP suite and 1 lab

Tampa, USA (FL)

  • Pharmaceutical and Biotech market-segment focus (Small molecule)
    • Preformulation- Polymorph identification, salt screen/selection
    • Analytical Development Services- API characterization, analytical method development and qualification, method transfer, release and stability testing
    • Formulation Development- Tablets, capsules, oral liquid dosage forms
  • Clinical and small-scale commercial manufacturing
  • 4 locations in Tampa for dedicated service areas
    • Headquarters (71,000 ft.2)- 2 preformulation suites; 14 formulation development suites (4 suites dedicated to potent compounds); analytical lab
    • Dedicated cGMP and small-scale commercial CTM facility
    • Dedicated global clinical supplies and packaging facility- 2 suites dedicated to primary packaging; 7 suites dedicated to secondary packaging
    • Dedicated distribution and logistics facility

Colmar, France

  • Health and Nutrition market-segment focus
  • 3 production lines for liquid-fill hard capsule (Licaps®)
  • Manufactures to European and FDA food regulations
  • Co-located product development site

Sagamihara, Japan

  • Health and Nutrition market-segment focus
  • Liquid-fill hard capsule (Licaps®) focus
  • Licaps® capacity of annual capacity > 400M units
  • Co-located product development site
Manufacturing footprint

Related Links

Dosage Forms Solutions overview

Powered by GlobalLink OneLink SoftwarePowered By OneLink